Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma

Kazuko Fujiwara, Tomomi Egawa-Takata, Yutaka Ueda, Toshihiro Kimura, Kiyoshi Yoshino, Masami Fujita, Takashi Miyatake, Yukinobu Ohta, Shoji Kamiura, Takayuki Enomoto, Tadashi Kimura, Kazuko Fujiwara, Tomomi Egawa-Takata, Yutaka Ueda, Toshihiro Kimura, Kiyoshi Yoshino, Masami Fujita, Takashi Miyatake, Yukinobu Ohta, Shoji Kamiura, Takayuki Enomoto, Tadashi Kimura

Abstract

Purpose: Recently a combination of paclitaxel and carboplatin (TC) (without an anthracycline) has begun to be used as an adjuvant or remission induction therapy, without any critical supportive evidence of its efficacy relative to a combination chemotherapy of taxane, platinum and anthracycline such as TEC (paclitaxel, epirubicin and carboplatin). The aim of our present study was to conduct the required clinical evaluations of the relative effectiveness of TC compared to TEC.

Methods: A retrospective comparison between the efficacy of TEC and TC regimens used for endometrial carcinoma at the Osaka University Hospital and the Osaka Medical Center for Cancer and Cardiovascular Diseases in Osaka, Japan, respectively, from 1999 to 2009 was performed. The clinical characteristics of the patients who received either TEC or TC were not significantly different, and TEC and TC therapies were initiated based on similar indications for chemotherapy. TEC regimen was paclitaxel (150 mg/m(2)), epirubicin (50 mg/m(2)) and carboplatin (AUC 4). TC regimen consisted of paclitaxel (175 mg/m(2)) and carboplatin (AUC 5).

Results: TEC was demonstrated to provide significantly better survival than TC as an adjuvant therapy for resected Stage III/IV diseases (p = 0.017 for progression-free survival and p = 0.014 for overall survival, by the log-rank test). However, in recurrent or more advanced cases, TC and TEC demonstrated similar effects on survival (p = 0.55 for progression-free survival and p = 0.63 for overall survival).

Conclusions: TEC should be offered as an adjuvant therapy to Stage III/IV patients. TC may be considered for recurrent or unresectable cases as a remission induction therapy.

Figures

Fig. 1
Fig. 1
PFS and OS of TEC and TC groups for unresectable or recurrent diseases. Both PFS and OS were not demonstrated to be significantly different between the TEC and TC groups (p = 0.63 and p = 0.55 by log-rank test, respectively). Solid line TEC group. Broken line TC group
Fig. 2
Fig. 2
PFS and OS of TEC and TC groups for adjuvant therapy (Stage III/IV). Both PFS and OS were significantly better in the TEC group than the TC group (p = 0.017 and p = 0.014 by the log-rank test, respectively). Solid line TEC group. Broken line TC group

References

    1. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology. 6. St. Louis: Mosby; 2002.
    1. Berek JS. Novak’s Gynecology. 13. Baltimore: William and Wilkins; 2002.
    1. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA, Gynecologic Oncology Group Study Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36–44. doi: 10.1200/JCO.2004.00.7617.
    1. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21:107–113.
    1. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902–3908. doi: 10.1200/JCO.2004.02.088.
    1. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62:278–281. doi: 10.1006/gyno.1996.0227.
    1. Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996;7:861–863.
    1. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159–2166. doi: 10.1200/JCO.2004.07.184.
    1. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, Sessa C. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8:969–972. doi: 10.1023/A:1008221310453.
    1. Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA, Hellenic Co-operative Oncology Group Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol. 2008;110:87–92. doi: 10.1016/j.ygyno.2008.03.004.
    1. Sovak MA, DuPont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR, Aghajanian C. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer. 2007;17:197–203. doi: 10.1111/j.1525-1438.2006.00746.x.
    1. Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008;109:250–254. doi: 10.1016/j.ygyno.2008.01.028.
    1. Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P, Amant F. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer. 2009;19:1147–1151. doi: 10.1111/IGC.0b013e3181ad3dcb.
    1. Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett. 2006;241:289–300. doi: 10.1016/j.canlet.2005.10.035.
    1. World Health Organization . Handbook of Reporting Results of Cancer Treatment No. 48. Geneva: WHO Offset Publication; 1979.
    1. Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008;109:250–254. doi: 10.1016/j.ygyno.2008.01.028.
    1. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329. doi: 10.1093/jnci/djg036.
    1. Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, Miyatake T, Fujita M, Yoshino K, Nakashima R, Okazawa M, Tsutsui T, Morishige K, Kimura T, Yamasaki M, Nishizaki T, Nagamatsu M, Ito K, Asada M, Ogita K, Wakimoto A, Yamamoto T, Nishio Y, Enomoto T (2011) Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy. Cancer Chemother Pharmacol 68:1603–1610

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する